share_log

Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology...

Benzinga ·  Dec 5, 2024 20:38

Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology Immuno-oncology Annual Congress 2024

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment